MA43717A - Anticorps anti-tnf et fragments fonctionnels de ceux-ci - Google Patents

Anticorps anti-tnf et fragments fonctionnels de ceux-ci

Info

Publication number: MA43717A
Authority: MA; Morocco
Prior art keywords: functional fragments; tnf antibodies; tnf; antibodies; fragments
Prior art date: 2016-03-17

Application number

MA043717A

Other languages

English (en)

Other versions

MA43717B1 (fr

Inventor

Esther Maria Furrer

Tea Gunde

Sebastian Meyer

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2017-03-16

Publication date

2018-11-28

2017-03-16 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2018-11-28 Publication of MA43717A publication Critical patent/MA43717A/fr

2023-11-30 Publication of MA43717B1 publication Critical patent/MA43717B1/fr

Links

239000012634 fragment Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

MA43717A 2016-03-17 2017-03-16 Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci MA43717B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16160907.8A EP3219726B1 (fr)	2016-03-17	2016-03-17	Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
PCT/EP2017/056237 WO2017158092A1 (fr)	2016-03-17	2017-03-16	Anticorps anti-tnfα et fragments fonctionnels de ceux-ci

Publications (2)

Publication Number	Publication Date
MA43717A true MA43717A (fr)	2018-11-28
MA43717B1 MA43717B1 (fr)	2023-11-30

Family

ID=55542576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA43717A MA43717B1 (fr)	2016-03-17	2017-03-16	Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci

Country Status (39)

Country	Link
US (3)	US11459383B2 (fr)
EP (3)	EP3219726B1 (fr)
JP (2)	JP7129398B2 (fr)
KR (2)	KR20220158877A (fr)
CN (1)	CN109071650B (fr)
AR (1)	AR107917A1 (fr)
AU (1)	AU2017235387A1 (fr)
BR (1)	BR112018016667A2 (fr)
CA (1)	CA3011784C (fr)
CL (1)	CL2018002649A1 (fr)
CO (1)	CO2018009783A2 (fr)
CR (1)	CR20180448A (fr)
CY (1)	CY1123784T1 (fr)
DK (2)	DK3219726T3 (fr)
EA (1)	EA039760B1 (fr)
ES (2)	ES2836349T3 (fr)
FI (1)	FI3430043T3 (fr)
GE (1)	GEP20217307B (fr)
HR (2)	HRP20231464T1 (fr)
HU (2)	HUE052773T2 (fr)
IL (1)	IL261031A (fr)
JO (2)	JOP20170064B1 (fr)
LT (2)	LT3219726T (fr)
MA (1)	MA43717B1 (fr)
MD (1)	MD3430043T2 (fr)
MX (1)	MX2018011258A (fr)
MY (1)	MY194041A (fr)
PH (1)	PH12018501907A1 (fr)
PL (2)	PL3219726T3 (fr)
PT (2)	PT3219726T (fr)
RS (2)	RS61374B1 (fr)
SA (1)	SA518400027B1 (fr)
SG (1)	SG11201807062RA (fr)
SI (2)	SI3219726T1 (fr)
TN (1)	TN2018000298A1 (fr)
TW (2)	TWI784945B (fr)
UY (1)	UY37157A (fr)
WO (1)	WO2017158092A1 (fr)
ZA (4)	ZA202108602B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108884156B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
EA039201B1 (ru)	2016-03-17	2021-12-16	Нумаб Инновейшн Аг	Антитела к фно и их функциональные фрагменты
EP3219727B1 (fr)	2016-03-17	2020-12-16	Tillotts Pharma AG	Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
EP3456738A1 (fr) *	2017-09-19	2019-03-20	Tillotts Pharma Ag	Variantes d'anticorps
PL3456736T3 (pl) *	2017-09-19	2021-09-13	Tillotts Pharma Ag	Warianty przeciwciała
EP3456737B1 (fr) *	2017-09-19	2024-02-14	Tillotts Pharma Ag	Variantes d'anticorps
WO2020114616A1 (fr)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ATE356869T1 (de)	1990-01-12	2007-04-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es)	1990-08-29	1997-12-16	Genpharm Int	Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (fr)	1991-05-17	2005-02-23	Merck & Co. Inc.	Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
WO1993011236A1 (fr)	1991-12-02	1993-06-10	Medical Research Council	Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
AU5632296A (en)	1995-04-27	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
WO1996034096A1 (fr)	1995-04-28	1996-10-31	Abgenix, Inc.	Anticorps humains derives de xeno-souris immunisees
CN103275221B (zh) *	1996-02-09	2016-08-17	艾伯维生物技术有限公司	结合人TNFα的人抗体
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
WO1998024893A2 (fr)	1996-12-03	1998-06-11	Abgenix, Inc.	MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
JP3876002B2 (ja)	1997-04-14	2007-01-31	ミクロメート・アクチエンゲゼルシャフト	抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
ATE384792T1 (de)	1998-11-18	2008-02-15	Genentech Inc	Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
AU2006255415B2 (en)	2005-06-07	2011-10-06	Esbatech, An Alcon Biomedical Research Unit Llc	Stable and soluble antibodies inhibiting TNFalpha
ES2861592T3 (es)	2008-06-25	2021-10-06	Novartis Ag	Anticuerpos estables y solubles que inhiben el TNF
CN102164958A (zh)	2008-06-25	2011-08-24	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	使用通用抗体构架进行的兔抗体的人源化
JP5579713B2 (ja)	2008-07-10	2014-08-27	エスバテック − アノバルティスカンパニーエルエルシー	高分子の送達増強のための方法および組成物
NZ603045A (en) *	2010-04-07	2014-11-28	Abbvie Inc	Tnf-alpha binding proteins
EP2593476A2 (fr)	2010-07-16	2013-05-22	Ablynx N.V.	Molécules de liaison à un antigène à domaine unique modifiées et leurs utilisations
US9096669B2 (en) *	2010-09-30	2015-08-04	Chengdu Kanghong Biotechnologies Co., Ltd.	Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same
AU2014301629B2 (en)	2013-06-26	2020-02-06	Numab Therapeutics AG	Novel antibody frameworks
US9416197B2 (en) *	2013-11-01	2016-08-16	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
WO2015144852A1 (fr) *	2014-03-26	2015-10-01	Delenex Therapeutics Ag	Éléments de liaison dirigés contre tnf alpha
EP3219727B1 (fr)	2016-03-17	2020-12-16	Tillotts Pharma AG	Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
CN108884156B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
EA039201B1 (ru)	2016-03-17	2021-12-16	Нумаб Инновейшн Аг	Антитела к фно и их функциональные фрагменты

2016
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/fr active Active
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
2017
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-16 DK DK17710748.9T patent/DK3430043T3/da active
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 EP EP23192170.1A patent/EP4275745A3/fr active Pending
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/fr active Application Filing
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Application Discontinuation
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 CA CA3011784A patent/CA3011784C/fr active Active
- 2017-03-16 BR BR112018016667A patent/BR112018016667A2/pt unknown
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/fr active Active
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 AU AU2017235387A patent/AU2017235387A1/en active Pending
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active IP Right Grant
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
2018
- 2018-08-07 IL IL261031A patent/IL261031A/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/ar unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US20230272059A1/en active Pending
- 2022-10-03 US US17/958,759 patent/US20230279091A1/en active Pending

Also Published As

Publication number	Publication date
ZA202108599B (en)	2022-03-30
MD3430043T2 (ro)	2024-02-29
LT3219726T (lt)	2021-01-25
HRP20231464T1 (hr)	2024-03-01
MY194041A (en)	2022-11-09
PL3430043T3 (pl)	2024-03-11
US20210198353A1 (en)	2021-07-01
WO2017158092A1 (fr)	2017-09-21
AR107917A1 (es)	2018-06-28
EA201891788A1 (ru)	2019-01-31
PT3430043T (pt)	2023-11-23
US11459383B2 (en)	2022-10-04
ES2836349T3 (es)	2021-06-24
EP3430043A1 (fr)	2019-01-23
UY37157A (es)	2017-10-31
ZA202108602B (en)	2022-03-30
HUE064238T2 (hu)	2024-02-28
KR20180120149A (ko)	2018-11-05
EP3219726A1 (fr)	2017-09-20
PT3219726T (pt)	2020-12-15
FI3430043T3 (fi)	2023-11-17
MA43717B1 (fr)	2023-11-30
JOP20210085A1 (ar)	2023-01-30
MX2018011258A (es)	2019-02-13
TW202311288A (zh)	2023-03-16
RS61374B1 (sr)	2021-02-26
US20230279091A1 (en)	2023-09-07
DK3430043T3 (da)	2023-11-27
AU2017235387A1 (en)	2018-09-27
ZA202108600B (en)	2022-03-30
ZA202108601B (en)	2022-03-30
IL261031A (en)	2018-10-31
CL2018002649A1 (es)	2018-11-09
LT3430043T (lt)	2023-12-27
CN109071650B (zh)	2022-05-13
JP2022130407A (ja)	2022-09-06
TN2018000298A1 (en)	2020-01-16
HUE052773T2 (hu)	2021-05-28
PL3219726T3 (pl)	2021-07-19
US20230272059A1 (en)	2023-08-31
KR102470235B1 (ko)	2022-11-24
EP4275745A2 (fr)	2023-11-15
HRP20210123T1 (hr)	2021-03-05
CO2018009783A2 (es)	2018-09-28
ES2963221T3 (es)	2024-03-26
SI3430043T1 (sl)	2024-01-31
CA3011784C (fr)	2024-04-23
SA518400027B1 (ar)	2022-03-06
CY1123784T1 (el)	2022-05-27
PH12018501907A1 (en)	2019-06-17
EP3430043B1 (fr)	2023-08-30
SG11201807062RA (en)	2018-09-27
TWI784945B (zh)	2022-12-01
TW201739766A (zh)	2017-11-16
GEP20217307B (en)	2021-10-25
CA3011784A1 (fr)	2017-09-21
CR20180448A (es)	2019-01-25
JP7129398B2 (ja)	2022-09-01
BR112018016667A2 (pt)	2019-02-05
CN109071650A (zh)	2018-12-21
JP2019512268A (ja)	2019-05-16
RS64830B1 (sr)	2023-12-29
JOP20170064B1 (ar)	2021-08-17
EA039760B1 (ru)	2022-03-10
DK3219726T3 (da)	2020-12-07
EP4275745A3 (fr)	2023-12-20
SI3219726T1 (sl)	2021-02-26
TWI829444B (zh)	2024-01-11
EP3219726B1 (fr)	2020-12-02
KR20220158877A (ko)	2022-12-01

Publication	Publication Date	Title
MA46525A (fr)	2019-08-21	Anticorps anti-lag-3 et compositions
IL265800A (en)	2019-06-30	Anti-lag-3 antibodies and methods of using them
IL272274A (en)	2020-03-31	Antibodies 4H-7B methods for their use
MA44659A (fr)	2021-04-14	Anticorps anti-tim-3 et compositions
KR102162129B9 (ko)	2023-02-08	항-갈렉틴-9 항체 및 이의 용도
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
DK3618863T3 (da)	2023-08-21	Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
MA55347A (fr)	2022-01-26	Anticorps anti-lag3 et fragments de fixation à l'antigène
SG10201912879YA (en)	2020-02-27	Anti-sirp-alpha antibodies and methods of use thereof
MA43576A (fr)	2018-11-14	Anticorps anti-lag3 et fragments de fixation à l'antigène
DK3601358T3 (da)	2023-07-31	Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
SG10201912563XA (en)	2020-02-27	Anti-tim-3 antibodies and methods of use thereof
DK3653221T3 (da)	2022-10-24	Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
MA43717A (fr)	2018-11-28	Anticorps anti-tnf et fragments fonctionnels de ceux-ci
MA42243A (fr)	2018-05-02	Anticorps de facteur xi et méthodes d'utilisation
EA201790984A1 (ru)	2018-05-31	Анти-cd79b антитела и способы их применения
MA49726A (fr)	2020-06-10	Formulation d'anticorps anti-cgrp
EA201691610A8 (ru)	2018-05-31	Анти-jagged1 антитела и способы применения
MA43738A (fr)	2018-11-28	Anticorps anti-tnfalpha et leurs fragments fonctionnels
IL264528B1 (en)	2023-05-01	fcrn antibodies and methods of using them
ZA202003695B (en)	2023-01-25	Anti-neuropilin antigen-binding proteins and methods of use thereof
IL267673A (en)	2019-08-29	Broad neutralizing antibodies against hiv-1 and methods of using them
CR20180296A (es)	2018-08-10	ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO
IL265957A (en)	2019-05-30	Anti-c1s antibodies and methods of using them
MA43715A (fr)	2018-11-28	Anticorps anti-tnf et fragments fonctionnels correspondants